SFSIG
PRTK

San Francisco Sentry Investment Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

San Francisco Sentry Investment Group’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-200
Closed -$1K – 957
2019
Q3 		$1K Buy
+200
New +$800 ﹤0.01% 886

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

San Francisco Sentry Investment Group's PRTK Position: Q4 2019 in Review

San Francisco Sentry Investment Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2019, closing a stake of 200 shares — an estimated $1K sold.

San Francisco Sentry Investment Group first reported a position in PRTK in Q3 2019 and held it in 1 quarter. The position peaked at $1K in Q3 2019. 93 funds tracked by Wall St. Rank hold PRTK as of Q4 2019.

  • San Francisco Sentry Investment Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 200 Paratek Pharmaceuticals, Inc. shares in Q4 2019, an estimated $1K.
  • San Francisco Sentry Investment Group first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • San Francisco Sentry Investment Group's Paratek Pharmaceuticals, Inc. position peaked at $1K in Q3 2019.
  • 93 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2019.

Based on San Francisco Sentry Investment Group's 13F filing for Q4 2019, filed 30 Jan 2020.